Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP705 for Advanced Liver Tumors
NCT04676633Phase 1Completed
- Sponsor
- Sirnaomics
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirna-tgf-b1 + sirna-cox-2 in cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC) and liver metastases (5 cohorts), sponsored by Sirnaomics. Primary endpoints: Maximum Tolerated Dose at 28 days and Limited Dose Toxicity at 28 days. Started Mar 2021; status: completed.
02
Drugs
sirna-tgf-b1 + sirna-cox-2
03
Conditions
cholangiocarcinoma (CCA)hepatocellular carcinoma (HCC)liver metastases
Beyond the preview
Go deeper on NCT04676633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676633.